AIMS: Schizophrenia patients have a mortality rate two to three-fold higher than that of the general population. Despite the disorder's widespread recognition, how and to what extent autonomic nervous system (ANS) activity contributes to schizophrenia remains inconclusive. The aim of the present study, therefore, was to determine the extent of ANS activity depression with respect to healthy, well-matched control subjects and the severity of psychiatric disorders as determined using the Global Assessment of Functioning (GAF) scale among schizophrenia patients with special reference to antipsychotic dose. METHODS: This study included 71 schizophrenia patients and 72 healthy controls. ANS activity was assessed by means of heart rate variability power spectral analysis. RESULTS: ANS-related spectral parameters were three-four-fold lower in the patients compared to the control group (P < 0.01). Furthermore, when the patients without cardiovascular complications were classified according to GAF score, overall ANS (P = 0.033) and parasympathetic nervous system (PNS) activity (P = 0.025) were significantly reduced in the low-GAF as compared to the high-GAF group. Partial correlation analyses demonstrated that ANS activity was significantly correlated with GAF score while statistically eliminating the effects of age, gender, body mass index, antipsychotic dose, and lipid profiles of the patient population. CONCLUSION: The significantly lower ANS activity in the low-GAF group suggests that such autonomic functional depression could be associated with the severity of schizophrenia. The present data further imply that schizophrenia patients with more depressed overall ANS and PNS activity might encounter increasing risks for cardiovascular events such as sudden death.
AIMS: Schizophreniapatients have a mortality rate two to three-fold higher than that of the general population. Despite the disorder's widespread recognition, how and to what extent autonomic nervous system (ANS) activity contributes to schizophrenia remains inconclusive. The aim of the present study, therefore, was to determine the extent of ANS activity depression with respect to healthy, well-matched control subjects and the severity of psychiatric disorders as determined using the Global Assessment of Functioning (GAF) scale among schizophreniapatients with special reference to antipsychotic dose. METHODS: This study included 71 schizophreniapatients and 72 healthy controls. ANS activity was assessed by means of heart rate variability power spectral analysis. RESULTS: ANS-related spectral parameters were three-four-fold lower in the patients compared to the control group (P < 0.01). Furthermore, when the patients without cardiovascular complications were classified according to GAF score, overall ANS (P = 0.033) and parasympathetic nervous system (PNS) activity (P = 0.025) were significantly reduced in the low-GAF as compared to the high-GAF group. Partial correlation analyses demonstrated that ANS activity was significantly correlated with GAF score while statistically eliminating the effects of age, gender, body mass index, antipsychotic dose, and lipid profiles of the patient population. CONCLUSION: The significantly lower ANS activity in the low-GAF group suggests that such autonomic functional depression could be associated with the severity of schizophrenia. The present data further imply that schizophreniapatients with more depressed overall ANS and PNS activity might encounter increasing risks for cardiovascular events such as sudden death.
Authors: Holly K Hamilton; Jane C Sun; Michael F Green; Kimmy S Kee; Junghee Lee; Mark Sergi; Gretchen L Sholty; Kristopher I Mathis; Christopher Jetton; Terrance J Williams; Robert Kern; William Horan; Alan Fiske; Kenneth L Subotnik; Joseph Ventura; Gerhard Hellemann; Keith H Nuechterlein; Cindy M Yee Journal: J Abnorm Psychol Date: 2014-10-13
Authors: Janine A E M van Venrooij; Sjoerd B A H A Fluitman; Jeroen G Lijmer; Annemieke Kavelaars; Cobi J Heijnen; Herman G M Westenberg; René S Kahn; Christine C Gispen-de Wied Journal: Schizophr Bull Date: 2010-06-17 Impact factor: 9.306
Authors: H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai Journal: J Psychopharmacol Date: 2008-09-18 Impact factor: 4.153